Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
Cyclophosphamide
/ administration & dosage
Disease-Free Survival
Doxorubicin
/ administration & dosage
Female
Gene Expression Regulation, Neoplastic
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Paclitaxel
/ administration & dosage
Receptor, ErbB-2
/ metabolism
Survival Rate
Trastuzumab
/ administration & dosage
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2019
15 07 2019
Historique:
received:
11
07
2018
revised:
18
12
2018
accepted:
21
02
2019
pubmed:
28
2
2019
medline:
23
9
2020
entrez:
28
2
2019
Statut:
ppublish
Résumé
Young age has been shown to be an independent predictor of poor outcome in breast cancer. In HER2-positive breast cancer, the effects of aging remain largely unknown. A total of 4,547 patients were included [3,132 from North Central Cancer Treatment Group (NCCTG) N9831 and 1,415 from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31]. Pathologic stromal tumor-infiltrating lymphocyte (sTIL) and molecular tumor infiltrating lymphocyte (mTIL) signatures were evaluated. In NCCTG N9831, comparable benefit of trastuzumab was observed in all patients [age ≤ 40; HR, 0.43; 95% confidence interval (CI), 0.28-0.66; Among patients treated with trastuzumab, there was no significant difference in outcome related to age. Our study suggests that trastuzumab can negate the poor prognosis associated with young age.
Identifiants
pubmed: 30808774
pii: 1078-0432.CCR-18-2206
doi: 10.1158/1078-0432.CCR-18-2206
pmc: PMC6634998
mid: NIHMS1522769
doi:
Substances chimiques
Biomarkers, Tumor
0
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Paclitaxel
P88XT4IS4D
Banques de données
ClinicalTrials.gov
['NCT00005970', 'NCT00004067']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
4422-4430Subventions
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196171
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196067
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189867
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
Annu Rev Immunol. 2000;18:529-60
pubmed: 10837068
Ann Oncol. 2002 Feb;13(2):273-9
pubmed: 11886005
Curr Opin Immunol. 2004 Apr;16(2):151-6
pubmed: 15023406
Exp Gerontol. 2004 Apr;39(4):567-76
pubmed: 15050292
Clin Breast Cancer. 2004 Apr;5(1):63-9
pubmed: 15140287
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
J Clin Oncol. 2008 Jul 10;26(20):3324-30
pubmed: 18612148
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Clin Oncol. 2010 Jan 1;28(1):92-8
pubmed: 19933921
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
J Clin Oncol. 2011 Sep 1;29(25):3366-73
pubmed: 21768458
J Clin Oncol. 2011 Dec 1;29(34):4491-7
pubmed: 22042958
Aging health. 2011 Oct 1;7(5):707-718
pubmed: 22121388
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32
pubmed: 22124364
Nat Rev Cancer. 2012 Mar 22;12(4):278-87
pubmed: 22437872
Bioinformatics. 2012 Jun 1;28(11):1546-8
pubmed: 22513995
CA Cancer J Clin. 2012 Sep-Oct;62(5):281-2
pubmed: 22847535
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
J Clin Oncol. 2013 Jul 20;31(21):2692-8
pubmed: 23752109
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
Oncotarget. 2015 May 30;6(15):13688-702
pubmed: 25999348
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
JAMA Oncol. 2016 Jan;2(1):56-64
pubmed: 26469139
J Immunother Cancer. 2017 Feb 21;5:18
pubmed: 28239471
Sci Rep. 2017 Apr 25;7(1):1134
pubmed: 28442763
N Engl J Med. 2018 Jul 12;379(2):122-137
pubmed: 29863451
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
J Natl Cancer Inst Monogr. 1994;(16):35-42
pubmed: 7999467
Lancet. 1993 Apr 24;341(8852):1039-43
pubmed: 8096955
J Clin Oncol. 1994 May;12(5):888-94
pubmed: 8164038